CEO total compensation of approximately $2.77 million is modest for a small-cap biotech CEO, well within expected benchmarks for a company of Enanta's size and stage, and does not trigger the individual or aggregate pay-level thresholds. The pay mix is appropriately weighted toward variable and equity-based elements — stock options represent the largest single component, 20% of equity is tied to performance-based vesting conditions (research and development milestones and relative total shareholder return), and cash bonuses are tied to pre-established annual corporate objectives — so the pay-mix quality screen passes. Prior-year shareholder support was 93%, well above the 70% threshold, and no clawback or governance concerns are identified.

PricewaterhouseCoopers LLP is a Big 4 firm and appropriate for a company of Enanta's size and complexity; the proxy does not provide an auditor fee table with sufficient detail to compute a non-audit fee ratio, so no fee-ratio trigger fires, and the absence of confirmed tenure data means the tenure trigger cannot be applied — per policy, we vote FOR when tenure cannot be confirmed, noting the absence as a minor negative factor, and no material restatement issues are disclosed.